Cardiac-Specific Expression of the Hepatocyte Growth Factor (HGF) Under the Control of a TnIc Promoter Confers a Heart Protective Effect After Myocardial Infarction (MI)

ISSN: 1566-5232 (Print)
ISSN: 1875-5631 (Online)


Volume 14, 6 Issues, 2014


Download PDF Flyer




Current Gene Therapy

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 29th of 164 in Genetics & Heredity

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Ignacio Anegon
Director INSERM UMR 1064-Center for Research in Transplantation and Immunology
CHU de Nantes. 30, boulevard
Nantes
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 4.906
5 - Year: 4.087

Cardiac-Specific Expression of the Hepatocyte Growth Factor (HGF) Under the Control of a TnIc Promoter Confers a Heart Protective Effect After Myocardial Infarction (MI)

Author(s): Zhihui Xu, Zhengxian Tao, Zhuowen Xu, Yuefeng Yang, Hua Wang, Lisheng Wang, Zuze Wu, Qi Tan, Ningtian Zhou, Ming Zhang, Pengsheng Chen and Zhijian Yang

Affiliation: Department of Cardiology and Department of Geriatrics, The First affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, P.R. China.

Abstract

Objective: Uncontrolled therapeutic gene expression and neovascularization in non-specific tissues has lowered the safety of gene therapy. The aim of the study was to identify a cardiac-specific promoter to control target gene expression in heart tissue in vitro and in vivo. Methods: Adenovirus vectors containing the firefly luciferase or hepatocyte growth factor (HGF) genes under control of the Troponin I (TnIc) or Cytomegalievirus (CMV) promoters were transfected into cell lines or injected into the left ventricular wall of Sprague Dawley (SD) rats via thoracotomy. Myocardial infarction (MI) was induced immediately before direct injection. In vivo luciferase expression was assessed using a bioluminescence imaging system. Heart function was monitored via echocardiograph intermittently for eight weeks after injection. Results: The constitutively active CMV promoter yielded luciferase expression throughout the body while luciferase expression driven by the TnIc promoter was largely restricted to the hypoxic heart. The CMV promoter was more efficient, yielding 100-1000 fold more light output than the TnIc promoter. Four weeks after injection, we observed a significant decline in the ejection fraction (EF) in saline and Ad-Null groups but a 17% increase in the Ad-CMV-HGF group. No change in EF was observed in the Ad-TnIc-HGF group. Conclusions: The adenovirus vector combined with the TnIc promoter largely restricts gene-targeted therapy in the hypoxic heart and prevents heart failure after myocardial infarction.

Keywords: Troponin, promoter, HGF, luciferase.

Download Free Order Reprints Order Eprints Rights and Permissions

  
  



Article Details

Volume: 14
Issue Number: 1
First Page: 63
Last Page: 73
Page Count: 11
DOI: 10.2174/1566523214666140207104209
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science